Apr 20, 2026 06:45AM
Apr 20, 2026 06:45AM
Oct 21, 2025 07:30PM
Oct 21, 2025 07:30PM
May 30, 2024 10:30PM
Jan 8, 2024 06:30PM
Aug 23, 2023 06:45AM FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Aug 10, 2023 08:35AM
Jul 6, 2023 02:00AM
Apr 30, 2023 09:24PM
Apr 30, 2023 07:00PM
Feb 19, 2023 06:30PM
Dec 20, 2022 06:45AM
Dec 20, 2022 06:45AM Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advance
Aug 18, 2022 02:30AM
Jan 6, 2021 08:00AM
Oct 14, 2020 07:08AM
Oct 14, 2020 07:00AM
Dec 2, 2019 08:04AM
Dec 2, 2019 08:00AM
Dec 2, 2019 08:00AM Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Canc
Sep 16, 2019 08:00AM
Sep 16, 2019 08:00AM
Aug 21, 2019 02:00PM
Aug 21, 2019 02:00PM
May 29, 2018 08:00AM
Mar 19, 2018 04:16PM
Mar 19, 2018 04:15PM U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
Mar 19, 2018 04:15PM
Sep 12, 2017 10:00PM
Feb 22, 2016 04:10PM
Feb 22, 2016 04:10PM

15,423 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All